Pedro Henrique Shimiti Hashizume
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Henrique Shimiti Hashizume has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Leonardo Gomes da Fonseca
Instituto Do Cancer do Estado de São Paulo, Hospital das Clínicas Universidade São Paulo São Paulo Brazil
2 shared publications Andre Boonstra
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
1 shared publicationAndrea Bolomo
Gastroenterology Department, Hospital Privado Universitário de Córdoba, Instituto Universitario de Ciências Biomédicas de Córdoba, Córdoba, Argentina
1 shared publication- Claudia Pinto Oliveira
Universidade de São Paulo, Brasil
1 shared publication Cristina Zambrano
Department of Gastroenterology, Hospital de Especialidades Carlos Andrade Marín, Quito, Ecuador
1 shared publicationDomingo Balderramo
Gastroenterology Department, Hospital Privado Universitário de Córdoba, Instituto Universitario de Ciências Biomédicas de Córdoba, Córdoba, Argentina
1 shared publication
Latest Publications
- Open Access
- 25 January 2026
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 22 (CP)
Fanconi Syndrome Induced by Ifosfamide in a Young Adult with Ewing Sarcoma
Nitrogen mustards, including ifosfamide, have been used as antineoplastic agents since the mid-twentieth century. A rare but recognized complication of ifosfamide therapy is the development of type-II proximal renal tubular dysfunction, consistent with Fanconi syndrome. This adverse effect can occur at any age; however, it is more commonly described in pediatric populations, affecting up to 5% of children treated with ifosfamide. The purpose of the current report is to describe a case of a young adult male patient undergoing treatment with etoposide and ifosfamide for Ewing sarcoma. Upon admission, the patient presented with lower abdominal pain and hematuria; laboratory tests revealed electrolyte imbalances and urinary findings consistent with Fanconi syndrome. The patient received supportive care, including electrolyte replacement, and achieved full recovery.
- 25 January 2026
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 22 (CP)
Open AccessFanconi Syndrome Induced by Ifosfamide in a Young Adult with Ewing Sarcoma
Nitrogen mustards, including ifosfamide, have been used as antineoplastic agents since the mid-twentieth century. A rare but recognized complication of ifosfamide therapy is the development of type-II proximal renal tubular dysfunction, consistent with Fanconi syndrome. This adverse effect can occur at any age; however, it is more commonly described in pediatric populations, affecting up to 5% of children treated with ifosfamide. The purpose of the current report is to describe a case of a young adult male patient undergoing treatment with etoposide and ifosfamide for Ewing sarcoma. Upon admission, the patient presented with lower abdominal pain and hematuria; laboratory tests revealed electrolyte imbalances and urinary findings consistent with Fanconi syndrome. The patient received supportive care, including electrolyte replacement, and achieved full recovery.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2262-2273
Prognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study
Background: The systemic treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinase inhibitors, such as sorafenib (SOR), to immune checkpoint inhibitor-based combinations (IO). Despite these advances, there is a lack of simple, objective tools to stratify patient prognosis in clinical practice. While several laboratory parameters are known to correlate with outcomes, their combined utility across treatment types remains unclear. We aimed to evaluate the prognostic value of commonly available biomarkers and to develop a simplified score applicable to both SOR- and IO-treated patients. Methods: This retrospective cohort study analyzed patients with advanced or intermediate-stage HCC treated with first-line systemic therapy at a single center in Brazil from 2009 to 2024. Patients were stratified into a SOR cohort and an IO cohort. Baseline variables included demographics and biochemical markers. We assessed the association between survival and three baseline biomarkers: alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio (NLR). A prognostic score was developed in the SOR cohort by assigning one point to each adverse factor: AFP ≥200 ng/mL, ALBI grade 2–3, and NLR ≥3. Overall survival (OS) was estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox regression models. Results: The study included 440 patients in the SOR cohort and 32 in the IO cohort. In the SOR cohort. Most patients in both cohorts were Child-Pugh A, PS 0–1 and hepatitis C was the predominant etiology. AFP ≥200 ng/mL (Pvs. 2–3 points had significantly different OS (HR 2.2; 95% CI: 1.1–4.9; P=0.04). Conclusions: This simplified prognostic score, based on three routine laboratory parameters, stratifies survival outcomes in HCC patients receiving either sorafenib or immunotherapy. While further validation is needed in larger and more diverse populations, this tool may support individualized clinical counseling and risk-adapted trial design.
- 1 October 2025
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (5) , 2262-2273
Open AccessPrognostic value of a simplified score based on routine parameters in patients with hepatocellular carcinoma treated with systemic therapies: a retrospective cohort study
Background: The systemic treatment landscape for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinase inhibitors, such as sorafenib (SOR), to immune checkpoint inhibitor-based combinations (IO). Despite these advances, there is a lack of simple, objective tools to stratify patient prognosis in clinical practice. While several laboratory parameters are known to correlate with outcomes, their combined utility across treatment types remains unclear. We aimed to evaluate the prognostic value of commonly available biomarkers and to develop a simplified score applicable to both SOR- and IO-treated patients. Methods: This retrospective cohort study analyzed patients with advanced or intermediate-stage HCC treated with first-line systemic therapy at a single center in Brazil from 2009 to 2024. Patients were stratified into a SOR cohort and an IO cohort. Baseline variables included demographics and biochemical markers. We assessed the association between survival and three baseline biomarkers: alpha-fetoprotein (AFP), albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio (NLR). A prognostic score was developed in the SOR cohort by assigning one point to each adverse factor: AFP ≥200 ng/mL, ALBI grade 2–3, and NLR ≥3. Overall survival (OS) was estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were derived from Cox regression models. Results: The study included 440 patients in the SOR cohort and 32 in the IO cohort. In the SOR cohort. Most patients in both cohorts were Child-Pugh A, PS 0–1 and hepatitis C was the predominant etiology. AFP ≥200 ng/mL (Pvs. 2–3 points had significantly different OS (HR 2.2; 95% CI: 1.1–4.9; P=0.04). Conclusions: This simplified prognostic score, based on three routine laboratory parameters, stratifies survival outcomes in HCC patients receiving either sorafenib or immunotherapy. While further validation is needed in larger and more diverse populations, this tool may support individualized clinical counseling and risk-adapted trial design.
- Open Access
- 9 January 2025
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 21 (CP)
Analysis of the Impact of the SARS-CoV-2 Pandemic on the Stage and Access to Oncology Services in Brazil for the Treatment of Rectal Cancer
Cancer is a major social, public health, and economic challenge worldwide, accounting for 1 in 6 deaths globally, according to Globocan 2022. Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there has been a noticeable impact on the provision of services to oncology patients. The present study aimed to analyze the effect of the pandemic on access to healthcare services and disease staging at a specialized oncology hospital located in the state of São Paulo. Demographic, clinical, and access data were extracted from 3 electronic information systems, comparing 3 periods: prepandemic (2018–2019), pandemic (2020–2021), and postrestriction easing (2022 to June 2023). The results showed progression in the clinical stage of patients referred to for treatment from the pandemic period onwards. In the prepandemic period, approximately 9.4% of patients presented at clinical stage IV. During the pandemic, this percentage increased to 15.4%, and in the postrestriction easing period, it reached 17.8%. Although access to effective oncological treatment was improved during the pandemic, there was a noticeable progression in the clinical stage of the disease, which persisted after the easing of restrictions.
- 9 January 2025
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 21 (CP)
Open AccessAnalysis of the Impact of the SARS-CoV-2 Pandemic on the Stage and Access to Oncology Services in Brazil for the Treatment of Rectal Cancer
Cancer is a major social, public health, and economic challenge worldwide, accounting for 1 in 6 deaths globally, according to Globocan 2022. Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, there has been a noticeable impact on the provision of services to oncology patients. The present study aimed to analyze the effect of the pandemic on access to healthcare services and disease staging at a specialized oncology hospital located in the state of São Paulo. Demographic, clinical, and access data were extracted from 3 electronic information systems, comparing 3 periods: prepandemic (2018–2019), pandemic (2020–2021), and postrestriction easing (2022 to June 2023). The results showed progression in the clinical stage of patients referred to for treatment from the pandemic period onwards. In the prepandemic period, approximately 9.4% of patients presented at clinical stage IV. During the pandemic, this percentage increased to 15.4%, and in the postrestriction easing period, it reached 17.8%. Although access to effective oncological treatment was improved during the pandemic, there was a noticeable progression in the clinical stage of the disease, which persisted after the easing of restrictions.
- Open Access
- 25 November 2024
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 40, 100952
Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes
- 25 November 2024
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 40, 100952
Open AccessCholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes